The U.S. FDA has missed a key deadline to decide whether to grant full approval to Novavax's (NASDAQ:NVAX) COVID-19 vaccine.

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

Shares of Novavax Inc. NVAX slid 6.35% to $5.60 Thursday, on what proved to be an all-around dismal trading session for the ...

Bullish option flow detected in Novavax (NVAX) with 12,673 calls trading, 2x expected, and implied vol increasing almost 14 points to 90.76%.

Novavax (NVAX) issued the following update on the FDA BLA for the company’s COVID-19 vaccine: “Novavax can confirm that April 1, 2025, was the ...

In the latest trading session, Novavax (NVAX) closed at $5.98, marking a -0.33% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.67%. At the same time, the ...

US biotech Novavax (Nasdaq: NVAX) is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April ...

Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...

Novavax (NVAX) stock rebounds 2.5% after six days of losses amid FDA approval delays for its COVID-19 vaccine.

Shares of Novavax Inc. NVAX slipped 8.43% to $6.41 Monday, on what proved to be an all-around mixed trading session for the ...